Article in Genes & development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Agata L PatriotisLaboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, New York 10065, USA; alpat@mit.edu.ORCID 0000-0002-8237-975X
Douglas W BarrowsBioinformatics Resource Center, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0002-5774-6861
Yadira Soto-FelicianoLaboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0001-5118-8478
Marylene LeboeufLaboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0001-9536-6651
Dylan M MarchioneEpigenetics Institute, Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.ORCID 0000-0001-6941-0604
Michael-Christopher KeoghEpiCypher, Inc., Durham, North Carolina 27709, USA.ORCID 0000-0002-2219-8623
Thomas S CarrollBioinformatics Resource Center, The Rockefeller University, New York, New York 10065, USA.
Benjamin A GarciaEpigenetics Institute, Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Alexey A SoshnevLaboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0002-1713-3470
C David AllisLaboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, New York 10065, USA.
Funding
Shared Resources Core 2: Quantitative Proteomics CoreP01CA196539 · NCI · ROCKEFELLER UNIVERSITY · PI MAJEWSKI, JACEK · 2015 to 2024
$17.6M
Viral modulation of epitranscriptomic mechanismsR01AI118891 · NIAID · WASHINGTON UNIVERSITY · PI GARCIA, BENJAMIN A, WEITZMAN, MATTHEW D. · 2015 to 2025
$5.4M
Functional and Mechanistic Study of Histone Crotonylation in Hematological MalignanciesR01CA204639 · NCI · ROCKEFELLER UNIVERSITY · PI ALLIS, CHARLES DAVID, ARMSTRONG, SCOTT A · 2016 to 2020
$3.5M
Role of novel onco-histone mutations in B-cell malignanciesR01CA234561 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CESARMAN, ETHEL · 2019 to 2023
$3.3M
Quantitative mass spectrometry for comprehending epigenetic mechanisms in a new underlying neurological developmental disorderR01HD106051 · NICHD · WASHINGTON UNIVERSITY · PI Benjamin A Garcia · 2022 to 2026
$2.6M
High-throughput methyltransferase assays using recombinant nucleosome substratesR44GM117683 · NIGMS · EPICYPHER, INC. · PI SUN, ZU-WEN · 2018 to 2019
$1.7M
Barcoded nucleosomes for analyzing combinatorial epigenetic regulatorsR44GM116584 · NIGMS · EPICYPHER, INC. · PI SUN, ZU-WEN · 2017 to 2018
$1.6M
Development and Application of Chemical Biology Approaches for Understanding Protein ArginylationR01HL177113 · NHLBI · WASHINGTON UNIVERSITY · PI Benjamin A Garcia, Zongtao Lin · 2025 to 2026
$1.2M
Understanding mechanisms of transcriptional regulation by chromatin adaptor proteinsR00GM140265 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SOTO-FELICIANO, YADIRA M · 2022 to 2024
$747k
Understanding mechanisms of transcriptional regulation by chromatin adaptor proteinsK99GM140265 · NIGMS · ROCKEFELLER UNIVERSITY · PI SOTO-FELICIANO, YADIRA M · 2021 to 2021
$100k
Dissecting the molecular mechanisms of PRC2 dysregulation in cancerF99CA253687 · NCI · ROCKEFELLER UNIVERSITY · PI PATRIOTIS, AGATA EWA · 2020 to 2021
Polycomb group proteins maintain gene expression patterns established during early development, with Polycomb repressive complex 2 (PRC2) methyltransferase being a key regulator of cell differentiation, identity, and plasticity. Consequently, extensive somatic mutations in PRC2, including gain or loss of function (GOF or LOF), are observed in human cancers. The regulation of chromatin structure by PRC2 is critically dependent on its enhancer of zeste homolog 2 (EZH2) subunit, which catalyzes the methylation of histone H3 lysine 27 (H3K27). Recent structural studies of PRC2 revealed extensive conformational changes in the noncatalytic EZH2 N-terminal SANT1-binding domain (SBD) during PRC2 activation, though the functional significance remains unclear. Here, we investigated how the SBD regulates PRC2 function. The domain is highly conserved in metazoans and dispensable for PRC2 assembly and chromatin localization yet is required for genome-wide histone H3K27 methylation. Furthermore, we show that an intact SBD is necessary for the proliferation of EZH2-addicted lymphomas, and its deletion in the presence of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The conserved N-terminal SANT1-binding domain (SBD) of EZH2 regulates PRC2 activity. · full record | OpenQuestion